ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)

As there are limited clinical data for many of the reviewed agents, special attention must be given to promptly detect and report emerging infectious complications.